People · Operator
Named in public records as an officer, director or promoter · active 2011–2021 · Other Technology, Biotechnology, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| CrossChx, Inc. | — | Other Technology | Growth/Late | $838.6M | $11.8B | 2017 |
| Applied Proteomics, Inc. | — | Biotechnology | Series B | $50.4M | $1.1B | 2011 |
| Thrive Global Holdings, Inc. | — | Other | Series B | $30.2M | $501.8M | 2017 |
David Agus at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside David Agus on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Fred Harman | 1 | 11 |
| Taylor Greene | 1 | 9 |
| James C. Blair | 1 | 8 |
| James Blair | 1 | 8 |
| John Kuelper | 1 | 6 |
| CHRISTOPHER OLSEN | 1 | 5 |
| Peter Klemm | 1 | 3 |
| Arianna Huffington | 1 | 2 |
| Sean Lane | 1 | 2 |
| Kok Thay Lim | 1 | 2 |
| Rebecca Hellman | 1 | 1 |
| Carlton Fox | 1 | 1 |
| Bradley Mascho | 1 | 1 |
| Mark Bertolini | 1 | 1 |
| Dan Katz | 1 | 1 |
| Abigail Levy | 1 | 1 |
| Daniel Abrutyn | 1 | 1 |
| Daniel Hillis | 1 | 1 |
| Erik Holmlin | 1 | 1 |
| Peter C. Klemm | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.